Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

A Pilot Randomized, Multicenter, Open-Label, Active Comparator-Controlled Trial Of A CP-690,550-Based Regimen In De Novo Kidney Allograft Recipients

A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.

Inclusion Criteria:

• Recipient of first time kidney transplant
• Between the ages of 18 and 70 years, inclusive

Exclusion Criteria:

• Recipient of any non-kidney transplant